申请人:Oxeia Biopharmaceuticals, Inc.
公开号:US20170121385A1
公开(公告)日:2017-05-04
The present disclosure provides methods for treating a neurodegenerative condition or situation in a subject in need thereof, comprising administering to the subject an effective amount of a compound comprising ghrelin or a ghrelin variant.